Sub-study 1 cervical cancer (volrustomig monotherapy)

Clinical trials for Sub-study 1 cervical cancer (volrustomig monotherapy) explained in plain language.

Never miss a new study

Get alerted when new Sub-study 1 cervical cancer (volrustomig monotherapy) trials appear

Sign up with your email to follow new studies for Sub-study 1 cervical cancer (volrustomig monotherapy), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Trials to join now! 1

New immunotherapy combo shows promise for tough cancers

Disease control Recruiting now

This phase 2 trial is testing an experimental drug called volrustomig, either alone or with chemotherapy, in people with advanced cervical, head and neck, esophageal, or mesothelioma cancers. The study aims to see if the drug can shrink tumors and how safe it is. About 257 partic…

Matched conditions: SUB-STUDY 1 CERVICAL CANCER (VOLRUSTOMIG MONOTHERAPY)

Phase 2 • Sponsor: AstraZeneca • Aim: Disease control

Last updated Sep 13, 2026 00:00 UTC

Sub-study 1 cervical cancer (volrustomig monotherapy)

Get alerted when new Sub-study 1 cervical cancer (volrustomig monotherapy) trials appear

New immunotherapy combo shows promise for tough cancers